171 related articles for article (PubMed ID: 29379130)
21. CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels.
Lee S; Cho NY; Yoo EJ; Kim JH; Kang GH
Arch Pathol Lab Med; 2008 Oct; 132(10):1657-65. PubMed ID: 18834226
[TBL] [Abstract][Full Text] [Related]
22. Genome-wide methylation analysis identifies a core set of hypermethylated genes in CIMP-H colorectal cancer.
McInnes T; Zou D; Rao DS; Munro FM; Phillips VL; McCall JL; Black MA; Reeve AE; Guilford PJ
BMC Cancer; 2017 Mar; 17(1):228. PubMed ID: 28351398
[TBL] [Abstract][Full Text] [Related]
23. Differential regulation of CpG island methylation within divergent and unidirectional promoters in colorectal cancer.
Namba S; Sato K; Kojima S; Ueno T; Yamamoto Y; Tanaka Y; Inoue S; Nagae G; Iinuma H; Hazama S; Ishihara S; Aburatani H; Mano H; Kawazu M
Cancer Sci; 2019 Mar; 110(3):1096-1104. PubMed ID: 30637877
[TBL] [Abstract][Full Text] [Related]
24. Zinc-finger protein 545 is inactivated due to promoter methylation and functions as a tumor suppressor through the Wnt/β-catenin, PI3K/AKT and MAPK/ERK signaling pathways in colorectal cancer.
Xiang S; Xiang T; Xiao Q; Li Y; Shao B; Luo T
Int J Oncol; 2017 Sep; 51(3):801-811. PubMed ID: 28677721
[TBL] [Abstract][Full Text] [Related]
25. Distinct epigenetic signatures elucidate enhancer-gene relationships that delineate CIMP and non-CIMP colorectal cancers.
Chong A; Teo JX; Ban KH
Oncotarget; 2016 May; 7(19):28027-39. PubMed ID: 27049830
[TBL] [Abstract][Full Text] [Related]
26. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) and inversely with CIMP-low and CIMP-high.
Ogino S; Kawasaki T; Kirkner GJ; Ohnishi M; Fuchs CS
BMC Cancer; 2007 May; 7():72. PubMed ID: 17474983
[TBL] [Abstract][Full Text] [Related]
27. Dual-specificity phosphatase 5 regulates nuclear ERK activity and suppresses skin cancer by inhibiting mutant Harvey-Ras (HRasQ61L)-driven SerpinB2 expression.
Rushworth LK; Kidger AM; Delavaine L; Stewart G; van Schelven S; Davidson J; Bryant CJ; Caddye E; East P; Caunt CJ; Keyse SM
Proc Natl Acad Sci U S A; 2014 Dec; 111(51):18267-72. PubMed ID: 25489104
[TBL] [Abstract][Full Text] [Related]
28. WRN promoter methylation possibly connects mucinous differentiation, microsatellite instability and CpG island methylator phenotype in colorectal cancer.
Kawasaki T; Ohnishi M; Suemoto Y; Kirkner GJ; Liu Z; Yamamoto H; Loda M; Fuchs CS; Ogino S
Mod Pathol; 2008 Feb; 21(2):150-8. PubMed ID: 18084250
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype.
Bae JM; Kim JH; Kang GH
Histol Histopathol; 2013 May; 28(5):585-95. PubMed ID: 23341177
[TBL] [Abstract][Full Text] [Related]
30. Global differences in the prevalence of the CpG island methylator phenotype of colorectal cancer.
Advani SM; Advani PS; Brown DW; DeSantis SM; Korphaisarn K; VonVille HM; Bressler J; Lopez DS; Davis JS; Daniel CR; Sarshekeh AM; Braithwaite D; Swartz MD; Kopetz S
BMC Cancer; 2019 Oct; 19(1):964. PubMed ID: 31623592
[TBL] [Abstract][Full Text] [Related]
31. Clinicopathologic Risk Factor Distributions for MLH1 Promoter Region Methylation in CIMP-Positive Tumors.
Levine AJ; Phipps AI; Baron JA; Buchanan DD; Ahnen DJ; Cohen SA; Lindor NM; Newcomb PA; Rosty C; Haile RW; Laird PW; Weisenberger DJ
Cancer Epidemiol Biomarkers Prev; 2016 Jan; 25(1):68-75. PubMed ID: 26512054
[TBL] [Abstract][Full Text] [Related]
32. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic silencing of diacylglycerol kinase gamma in colorectal cancer.
Kai M; Yamamoto E; Sato A; Yamano HO; Niinuma T; Kitajima H; Harada T; Aoki H; Maruyama R; Toyota M; Hatahira T; Nakase H; Sugai T; Yamashita T; Toyota M; Suzuki H
Mol Carcinog; 2017 Jul; 56(7):1743-1752. PubMed ID: 28218473
[TBL] [Abstract][Full Text] [Related]
34. IGFBP7 is a p53-responsive gene specifically silenced in colorectal cancer with CpG island methylator phenotype.
Suzuki H; Igarashi S; Nojima M; Maruyama R; Yamamoto E; Kai M; Akashi H; Watanabe Y; Yamamoto H; Sasaki Y; Itoh F; Imai K; Sugai T; Shen L; Issa JP; Shinomura Y; Tokino T; Toyota M
Carcinogenesis; 2010 Mar; 31(3):342-9. PubMed ID: 19638426
[TBL] [Abstract][Full Text] [Related]
35. The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype.
Fang M; Ou J; Hutchinson L; Green MR
Mol Cell; 2014 Sep; 55(6):904-915. PubMed ID: 25219500
[TBL] [Abstract][Full Text] [Related]
36. Methylation of the 3p22 region encompassing MLH1 is representative of the CpG island methylator phenotype in colorectal cancer.
Wong JJ; Hawkins NJ; Ward RL; Hitchins MP
Mod Pathol; 2011 Mar; 24(3):396-411. PubMed ID: 21102416
[TBL] [Abstract][Full Text] [Related]
37. Low expression of gamma-glutamyl hydrolase mRNA in primary colorectal cancer with the CpG island methylator phenotype.
Kawakami K; Ooyama A; Ruszkiewicz A; Jin M; Watanabe G; Moore J; Oka T; Iacopetta B; Minamoto T
Br J Cancer; 2008 May; 98(9):1555-61. PubMed ID: 18414409
[TBL] [Abstract][Full Text] [Related]
38. Epigenetic profiling of synchronous colorectal neoplasias by quantitative DNA methylation analysis.
Ogino S; Brahmandam M; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
Mod Pathol; 2006 Aug; 19(8):1083-90. PubMed ID: 16699497
[TBL] [Abstract][Full Text] [Related]
39. Characterization of Chilean patients with sporadic colorectal cancer according to the three main carcinogenic pathways: Microsatellite instability, CpG island methylator phenotype and Chromosomal instability.
Wielandt AM; Hurtado C; Moreno C M; Villarroel C; Castro M; Estay M; Simian D; Martinez M; Vial MT; Kronberg U; López-Köstner F
Tumour Biol; 2020 Jul; 42(7):1010428320938492. PubMed ID: 32635826
[TBL] [Abstract][Full Text] [Related]
40. CHFR promoter methylation indicates poor prognosis in stage II microsatellite stable colorectal cancer.
Cleven AH; Derks S; Draht MX; Smits KM; Melotte V; Van Neste L; Tournier B; Jooste V; Chapusot C; Weijenberg MP; Herman JG; de Bruïne AP; van Engeland M
Clin Cancer Res; 2014 Jun; 20(12):3261-71. PubMed ID: 24928946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
